Short Communications 27
Schizophrenia 3 - Clinical (3)

[SC27-4] Vaccine response and immunity in patients with psychotic disorders: prospective study of SARS-CoV-2 and Pneumococcal vaccination

*Atheeshaan Arumuham^1,2,3,4, Yuya Mizuno^1,4,5, Oisin O'Brien^1,6, Maria Lobo⁴, Sita Parmar⁴, Luke Baxter⁴, Stephen Jolles⁷, Oliver D Howes^1,2,3,4,8 (1. Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, De Crespigny Park, London, SE5 8AF, UK, 2. Psychiatric Imaging Group, Medical Research Council, London Institute of Medical Sciences, Hammersmith Hospital, London W12 0NN, UK, 3. Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College London, Du Cane Road, London W12 0NN, UK, 4. South London and Maudsley NHS Foundation Trust, London, UK, 5. Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan, 6. Department of Psychiatry, Royal College of Surgeons in Ireland, Dublin, Ireland, 7. Immunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, UK, 8. H Lundbeck A/s, 3 Abbey View, Everard Close, St Albans, AL1 2PS, UK)

Keywords:Schizophrenia, Clozapine, SARS-CoV-2, Vaccine, Immunity